Mereo BioPharma Group PLC (NAS:MREO)

$ 4.05 -0.04 (-0.98%) Market Cap: 623.10 Mil Enterprise Value: 547.99 Mil PE Ratio: 0 PB Ratio: 7.94 GF Score: 36/100

Mereo Biopharma Group PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 20, 2023
Mereo Biopharma Group PLC Corporate Call Transcript
Mar 21, 2023
Mereo Biopharma Group PLC at Jefferies London Healthcare Conference Transcript
Nov 16, 2022
Mereo Biopharma Group PLC at SVB Leerink Global Healthcare (Virtual) Transcript
Feb 17, 2022
Mereo Biopharma Group PLC To Discuss ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors Call Transcript
Nov 30, 2021
Half Year 2020 Mereo BioPharma Group plc Earnings Call Transcript
Sep 29, 2020

$2.55 (-0.78%)

Earnings

Mereo Biopharma Group PLC Corporate Call Transcript

Mar 21, 2023 / 12:30PM GMT

Release Date Price: $0.865 (+16.89%)

Transcript

Operator

Good day and welcome to the Mereo Biopharma regulatory update conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Lee Roth, Senior Vice President of Investor Relations at Burns McClellan. Please go ahead.

Lee Roth

Burns McClellan Inc. - SVP, IR

Thanks, Jason. And once again, thanks to everybody for joining us today for the regulatory update on the alvelestat that program in alpha-1-antitrypsin deficiency disorder. Joining me on the call is Dr. Denise Scots-Knight, Chief Executive Officer at Mereo. Following prepared remarks by Dr. Scots-Knight, Dr. Jackie Parkin, SVP and Therapeutic Head, leading the clinical development of alvelestat for AATD-lung disease, and Dr. Suba Krishnan, Senior Vice President of Clinical Development, will join from a line for a Q&A session with the sell side.

Please note today's conference call will contain forward-looking statements, including statements regarding the company's expectations with respect to its proposed Phase 3 study evaluating

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.